FEM1B

Across TCGA pan-cancer cohorts, FEM1B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FEM1B data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher FEM1B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FEM1B expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

DLBC, UCEC, and STAD are the cancer types where FEM1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	24	view →
UCEC	DFS	Median	II,III,IV	1.000	0.438	.017	18	view →
STAD	DFS	Median	II,III,IV	1.000	0.335	.035	14	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FEM1B–DLBC (DFS)

Open the DLBC breakdown →